Lower-Risk MDS

Management - anemia - new stuff

imetelstat

  • telomerase inhibitor
  • IV, 2h infusion q4wks
  • "IMerge" trial (phase 2 complete, phase 3 finished recruiting)
  • R/R tfx burden (≥4 pRBC/8wks)
  • primary endpoint: transfusion independence ≥8wk
  • 37% reached primary endpoint
  • 42% >8wks, 32% >24wks, 29% >52wks
  • possibly disease-modifying (clonal burden decreased in some)
19 / 24